This document provides a short summary of this study for a general audience. You can
find more information in the scientific summaries of the study. Links to those
summaries are provided at the end of this document.
Study names
Short Title: A study to compare six different doses of nemiralisib with placebo when
added to regular medicine(s) in patients with moderate to severe worsening of chronic
obstructive pulmonary disease.
Full Scientific Title: A phase IIb, randomised (stratified), double-blind (sponsor open),
parallel-group, placebo-controlled, dose-finding study of nemiralisib (GSK2269557)
added to standard of care versus standard of care alone in participants diagnosed with
an acute moderate or severe exacerbation of chronic obstructive pulmonary disease.
Study Number: 200879
Who sponsored this study?
GlaxoSmithKline (GSK)
GSK Clinical Support Help Desk
Website: clinicalsupporthd.gsk.com/contact.html
Email: GSKClinicalSupportHD@gsk.com
General information about the clinical study
When was this study done?
The study started in November 2017 and ended in January 2019.
What was the main objective of this study?
Chronic obstructive pulmonary disease (COPD) is a long-term disease of the lungs that
makes it hard to breathe and gets worse over time. Patients with COPD have
inflammation in the airways and/or lungs. This inflammation can cause shortness of
breath, coughing, and chest tightness.
Use of the data and information contained in this Document is unrestricted, provided that it may not
be used in applications by others for regulatory approval of a product. While not required, when using
these data, we ask that proper credit or attribution of GSK as the source of the data be given. GSK
disclaims liability for all uses of the data by users of this Document, to the fullest extent permitted by
applicable law. No trademark, patent, or regulatory/data exclusivity rights held by GSK are waived,
licensed or otherwise affected.